Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience.

Background: Acute lymphoblastic leukemia (ALL) is a clonal disease that affects early lymphoid progenitors in the bone marrow. Minimal residual disease (MRD) is assessed by different methods to monitor disease kinetics after treatment.

Aim: to Assess MRD post-induction, at 6 and 12 months after intensive chemotherapy in adult patients with ALL.